Hello again svdh-ga,
In response to your clarification that you wished to accept the
information I mentioned previously plus additional sources, I am
providing the following to you:
=======================================
From Spire Corporation:
Spire Receives FDA Clearance to Market Hemodialysis Catheter
“The Company estimates that the dialysis catheter market is over $100
million in the U.S. and $250 million worldwide. The Company plans to
begin selling the product immediately through a nationwide network of
specialty medical product distributors.”
“Dialysis therapy is the only treatment available for kidney failure,
other than a kidney transplant. Currently, there are nearly 300,000
end-stage renal disease (ESRD) patients in the U.S. and nearly one
million worldwide. In the U.S. alone, nearly $15 billion is spent
annually to care for ESRD patients, most of whom rely on a catheter
for blood access at some point in their treatment.”
Spire Corpoartion: April 16, 2002
http://www.spirebiomedical.com/Biomedical/News/BM367.htm
=======================================
Infectious Diseases Society of America, the Society of Critical Care
Medicine, and the Society for Healthcare Epidemiology of America
Guidelines for the Management of Intravascular Catheter Related
Infections
“Each year in the United States, hospitals and clinics purchase >150
million intravascular devices for the administration of iv fluids,
medications, blood products, and parenteral nutrition fluids; to
monitor hemodynamic status; and to provide hemodialysis.”
“The majority of these devices are peripheral venous catheters, but >5
million CVCs are inserted each year. More than 200,000 nosocomial
bloodstream infections occur each year in the United States; most of
these infections are related to different types of intravascular
devicesin particular, the nontunneled CVC.”
Clinical Infectious Diseases 2001; 32:1249-1272
http://www.journals.uchicago.edu/CID/journal/issues/v32n9/001689/001689.html
=======================================
“The hemodialysis catheter market is estimated to be $95 million. The
LifeJet(TM) F-16 is also approved for use as an apheresis catheter,
which expands the market to well over $100 million. Apheresis is the
process commonly used to collect stem cells that are later returned to
the patient as part of cancer treatment.”
Source: Horizon Medical Products, Inc.
http://216.239.37.100/search?q=cache:SxK8fA-EvssJ:biz.yahoo.com/bw/030123/230064_1.html+million+hemodialysis+catheter+patients+in+the+US&hl=es&ie=UTF-8
=======================================
From Biolink Corporation:
“Over 300,000 patients in the U.S. were receiving dialysis therapy at
the end of 2001.”
“The patient population requiring dialysis is growing at approximately
7% annually.”
“Worldwide, approximately 1.4 million people will require dialysis by
2003.”
“Vascular access for hemodialysis costs the U.S. healthcare system
approximately $2 billion per year.”
“According to the United States Renal Data System (USRDS) data from
1997, the total costs for vascular access complications reached at
least $2 billion in the year 2000. These complications included
thrombosis, stenosis, infection, post-dialysis bleeding, and limb
ischemia. In 2000, approximately 80,000 new patients will receive
hemodialysis in the United States and an equal number will require
replacement access procedures. The overall numbers are daunting: at
the end of 1997, over 250,000 patients received hemodialysis treatment
in the United States. At an annual patient growth rate of 7 percent,
1.4 million people worldwide are expected to suffer from ESRD by
2003.”
Source: Biolink Corporation
http://www.biolink.com/hemo_about.html
=======================================
Catheter Industry To Grow At 10.4% Annually From 1996-2003
“American medical device manufacturers dominate the catheter industry,
producing 70 to 80 percent of the catheters used around the world. In
1997, worldwide sales of catheter products totaled approximately $7.3
billion, and are growing at a healthy pace of 10.4% annually.
The fastest growing segment of the catheter industry, the coronary
catheter market, is expected to reach $4 billion by 2003, growing at
11.2% annually.”
(. . .)
“The largest segment, however, is the renal market, which is comprised
primarily of urinary catheters and dialysis catheters. Currently being
a $4 billion segment, it is expected to reach $7.1 billion in 2003.
The best-known urology catheters are Foley catheters, which have been
commercially available since the 1930s. These catheters and others,
both internal and external condom-type catheters, are used for
incontinence, for dying patients, and often for bladder drainage
following surgery or an incapacitating injury or illness.”
-------------------------------------------------------------------
Market Forecasts to the Year 2003 by Product Type ($ Million)
-------------------------------------------------------------------
Categories of Catheters
Coronary
1996 2,261
1997 2,495
1998 2,758
2003 4,711
AAGR % 1998-2003 11.2
Renal
1996 3,708
1997 4,053
1998 4,444
2003 7,120
AAGR % 1998-2003 9.9
Infusion
1996 693
1997 763
1998 841
2003 1,370
AAGR % 1998-2003 10.2
Totals
1996 6,662
1997 7,311
1998 8,043
2003 13,201
AAGR % 1998-2003 10.4
-------------------------------------------------------------------
Sources:
BUSINESS COMMUNICATIONS COMPANY, INC
http://www.bccresearch.com/editors/RB-129.html
Medi-Source Asia
http://www.medisourceasia.com/glbl_trends/11.htm
=======================================
Challenges of Hemodialysis Access for High Risk Patients
(30 page PowerPoint Presentation)
On page 6:
“17% of patients in the U.S. are catheter based dialysis patients.”
“26% in Canada are catheter based dialysis patients.”
“22% in the UK are catheter based dialysis patients.”
On page 7:
Graph - Prevalence by access type by major market
On page 8:
Graph - Prevalence in % of access by major market
Source: The American College of Surgeons Website
http://www.facs.org/spring_meeting/2003/gs03glickman.pdf
=======================================
Temporary Venous Dialysis Catheter
“The catheter is used in patients who do not have an AVF or AVG but
who need hemodialysis urgently. It is used temporarily as a means of
access until an AVF or AVG can be inserted. The catheter is used
permanently in some people who cannot tolerate the standard methods of
access. It poses significant risk for infection and failure and often
must be replaced.
There are approximately 300,000 people on dialysis in the United
States. Some patients require dialysis in the hospital or clinic and
others have in-home dialyzers that they are trained to operate.”
Source: Nephrology Channel
http://www.nephrologychannel.com/rrt/hemodialysis.shtml
=======================================
INTEGRATING EXPERIENCE by George Abraham, MD, FACP
May 4, 2002
“In the US, about 5 million central venous catheters inserted
annually”
Johns Hopkins Bloomberg School of Public Health
http://www.jhsph.edu/Academics/MPH_Old/bloodstream_infections.ppt
=======================================
“In the United States, more than 150 million intravascular devices are
used every year; while the majority of these are meant to gain
peripheral intravenous access, it is estimated that more than 5
million central venous catheters are inserted each year.”
Johns Hopkins Bloomberg School of Public Health
http://www.jhsph.edu/Academics/MPH_Old/imphsamplepaper.pdf
=======================================
Biz Briefs: JUNE 13-19, 2003
About 5 million U.S. patients have catheters inserted every year.
“Nuvelo Inc. of Sunnyvale began dosing patients in a second trial of
ialfimiprase, used to treat blood clots blocking catheters. The trial
will be conducted with 100 patients nationwide. About 5 million U.S.
patients have catheters inserted every year. Of that, 20 to 25 percent
eventually become blocked. Nuvelo hopes to prove its catheters will
better reduce the risk of complications compared to current
therapies.”
Source: Silicon Valley Business Ink
http://www.svbizink.com/otherfeatures/briefs.asp?iid=304
=======================================
BBC News:
“About 400 million catheters are used every year across the world and
people who use them for a month or more can expect to suffer an
infection.”
http://news.bbc.co.uk/2/hi/uk_news/wales/south_east/3008221.stm
=======================================
Additional Information That May Interest You:
CMS Presentation
The latest Dialysis Findings of the United States Renal Data System
Click here to download PowerPoint file.
http://www.usrds.org/2002/pres/USRDS_CMS_presentation_2003.exe
United States Renal Data System - 2002 Annual Data Report
At this webpage you will find links to the following categories:
- Incidence & Prevalence
- Patients Characteristics
- Treatment Modalities
- Clinical Indicator of Care
- Preventive Health Care
- Morbidity & Hospitalization
- Pediatric ESRD
- Transplantation
- Survival
- Cardiovascular SSC
- Provider Characteristics
- Economic Costs of ESRD
- International Comparisons
Source: USRDS
http://www.usrds.org/adr.htm
=======================================
Search Criteria:
U.S. hemodialysis catheter patients
U.S. hemodialysis catheter patients million
“hemodialysis catheters” U.S.
Dialysis shunts
I hope this helps. If anything is unclear please request clarification
and I'll be glad to offer further assistance before you rate my answer
and close the question.
Best Regards,
Bobbie7-ga |
